Royalty Report: Drugs, Diagnostic, Cancer – Collection: 243451

$150.00

Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 10

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 10

Primary Industries

  • Drugs
  • Diagnostic
  • Cancer
  • Research
  • DNA
  • Therapeutic
  • Test/Monitoring
  • Drug Discovery
  • Device
  • Disease
  • nucleic acid
  • cardiac
  • ribonucleic acid
  • Medical

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 243451

License Grant
Licensor hereby grants to Licensee and its Affiliates a worldwide non-exclusive royalty-bearing license, without the right to sublicense, under the Patent Rights to make, use, and sell Licensed Products in the Field of Use.
License Property
Monomer Licensed Product shall mean a Licensed Product which is a monomer used in the synthesis of an oligonucleotide N3—>P5 phosphoramidate.

Oligonucleotide Licensed Product shall mean a Licensed Product which is an oligonucleotide N3—>P5 phosphoramidate.

Patents
5,599,922 – Oligonucleotide N3-P5 phosphoramidates hybridization and nuclease resistance properties
5,591,607 – Oligonucleotide N3.fwdarw.P5 phosphoramidates triplex DNA formation
5,631,135 – Oligonucleotide N3.fwdarw.P5 phosphoramidates hybridization and nuclease resistance properties

Phosphoramidate-based oligonucleotides represent a new class of synthetic nucleic acids that have demonstrated a number of potential advantages over earlier-generation oligonucleotide chemistries, including enhanced sequence-specific DNA and RNA binding activity, a high resistance to degradation, and improved cellular uptake and biodistribution. These properties offer significant potential for the development of improved synthetic nucleic acid molecules to be used in both therapeutic and diagnostic applications. Transgenomic currently supplies the modified building block compounds that Geron uses to synthesize novel therapeutic thio-phosphoramidate oligonucleotides that target cancer cells by inhibiting telomerase.

Transgenomic provides versatile and innovative research tools and related consumable products to the life sciences industry for the synthesis, separation, analysis and purification of nucleic acids and a wide variety of nucleic acid-based specialty chemicals. Through its nucleic acids business segment, Transgenomic provides specialty chemicals, including advanced nucleic acid building blocks and associated reagents, used in applications such as genetic diagnostics and therapeutics.

Field of Use
Field of Use shall mean Research Uses only for all of the Patent Rights and both Research and Therapeutic Uses for the Lynx Patents.  Research Uses shall mean all uses which are neither Therapeutic Uses, as defined below, nor Prohibited Uses, as defined below.  Therapeutic Uses shall mean the prevention, diagnosis or treatment of any human disease or medical condition, through the use of any product, service or application, including, without limitation, human clinical trials of a product, service or application; provided that Therapeutic Uses excludes Prohibited Uses.

IPSCIO Record ID: 280323

License Grant
Licensor grants to Licensee and its Affiliates a worldwide non-exclusive license, without the right to sublicense, under the Patent Rights to make, market, distribute, and sell Licensed Products and/or Monomer Licensed Products in the Research Field.
License Property
Licensor owns and is an exclusive licensee of proprietary technology relating to oligonucleotide N3—>P5 phosphoramidates, their manufacture, and their uses in a variety of fields, refered to as the Amidate Technology.

Monomer Licensed Product shall mean a Licensed Product which is a monomer used in the synthesis of an oligonucleotide N3->P5 phosphoramidate.

Field of Use
Licensee has expertise in nucleic acid chemistry and is in the business of manufacturing. marketing, selling, and distributing nucleic acid compounds.  This agreement is for use in the Research Field.

Research Field shall mean any use in the field of scientific or commercial research, excepting any use that involves treating humans in any way whatsoever for any condition or any use that involves diagnosis of, testing for, or detection of, a disease condition, or the predisposition or susceptibility thereto, or the clinical progress thereof.

IPSCIO Record ID: 280322

License Grant
Licensor grants a worldwide non-exclusive license, without the right to sublicense, under the Patent Rights to make, market, distribute, and sell Licensed Products and/or Monomer Licensed Products in the Research Field; provided, however, that Monomer Licensed Products shall be distributed or sold only to qualified licensees of Licensor under the Patent Rights.
License Property
Licensor owns and is an exclusive licensee of proprietary technology relating to oligonucleotide N3->P5 phosphoramidates, their manufacture, and their uses in a variety of fields.

Monomer Licensed Product shall mean a Licensed Product which is a monomer used in the synthesis of an oligonucleotide N3—>P5 phosphoramidate.

Field of Use
Licensee has expertise in nucleic acid chemistry and is in the business of manufacturing, marketing, selling, and distributing nucleic acid compounds, and this agreement is for in the Research Field.

Research Field shall mean any use in the field of scientific or commercial research, excepting any use that Involves treating humans in any way whatsoever for any condition or any use that involves diagnosis of, testing for, or detection of, a disease condition, or the predisposition or susceptibility thereto, or the clinical progress thereof.

IPSCIO Record ID: 314354

License Grant
By this amendment, the Parties now proceed with unilateral development of OGX-011 and Products.  As of the Amendment Effective Date, the original Collaboration is terminated.

Licensor grants the Canadian Licensee a worldwide, nonexclusive license, with the right to grant sublicenses, under the Licensor Core Technology, Core Technology Patents, Manufacturing Technology and Manufacturing Patents to research, develop, make, have made, use, gain regulatory approval, commercialize, sell, offer for sale, have sold, export and import OGX-011 and Products for all uses.

For Development, Commercialization and Regulatory Responsibilities, Licensee will have sole responsibility, including without limitation sole responsibility for all funding, resourcing and decision making, for all further development and commercialization with respect to OGX-011 and Products.

License Property
Licensor is discovering and developing RNA-targeted therapeutics, and have created an efficient and broadly applicable drug discovery platform leveraging our expertise in antisense oligonucleotide therapeutics.

OGX-011 is a second generation antisense inhibitor of Clusterin.  Clusterin means the gene target, official symbol CLU, which is also referred to as Testosterone Repressed Prostatic Message -2 (TRPM-2), and Sulphated Glycoprotein2 (SGP-2).

Licensors Core Technology includes the patents and excludes the Manufacturing Technology and Product-Specific Technology.

Field of Use
Licensee is a development stage enterprise committed to the development and commercialization of new cancer therapies. The product candidates OGX-011, OGX-427 and OGX-225 focus on mechanisms of treatment resistance in cancer patients and address treatment resistance by blocking the production of specific proteins which it believes promote survival of tumor cells and are over-produced in response to a variety of cancer treatments.

IPSCIO Record ID: 204355

License Grant
This amendment clarifies certain definitions and modifies the royalty rates.

In the original restated license, Licensor grants a world-wide exclusive license under Licensed Patents and Licensed Know-How, to make, use, offer to sell, sell and import Licensed Products in the Exclusive Licensed Field.

License Property
Licensor has certain know-how relating to the synthesis of MGB Oligonucleotides, including MGB Oligonucleotides containing modified bases, and the design of sequence-specific probes comprising such oligonucleotides.  MGB Oligonucleotide means Licensed Product comprising an oligonucleotide having a minor-groove binding moiety covalently attached.

The licensed know-how includes chemical structures, manufacturing methods and Algorithms, object code, source code and any other embodiments of methods or processes useful for predicting the melting temperature of MGB Oligonucleotides, whether patented, copyrighted, or not.

Field of Use
The Exclusive Licensed Field means the 5’-Nuclease Assay Field.  The 5’-Nuclease Assay Field means the detection of a nucleic acid sequence based on the cleavage of a nucleic acid probe that is hybridized to the nucleic acid sequence by a 5’ to 3’ nuclease activity of a polymerase enzyme.

IPSCIO Record ID: 383599

License Grant
For the Product License, Licensor grants an exclusive license, with the limited right to sublicense, under the Licensed IP to research, develop, make, have made, use, sell, offer for sale, have sold, import and export Products in the Territory for therapeutic purposes.

For the Limited Right to Sublicense, the Product License is sublicensable only in connection with a sublicense of a Product to any Affiliate of Licensee or to any Third Party,

License Property
Licensor has intellectual property to advance mipomersen and related compounds targeting apoB.

Mipomersen means mipomersen sodium, including all pharmaceutically acceptable salts, solvates, hydrates, hemihydrates, metabolites, pro-drug forms, stereoisomers, enantiomers, racemates and all optically active forms thereof.

apoB means apolipoprotein B.

Product means all pharmaceutical compositions, formulations, dosage forms, delivery systems and presentations that contain Mipomersen or any Follow-On Compound as an active ingredient.

ASO Product any preparation in final form for sale by prescription, over-the-counter or any other method for any indication, including human or animal use, which contains one or more oligonucleotides or an analog thereof that  selectively modulates protein synthesis at the nucleic acid level through the binding of such oligonucleotide to a complementary sequence.

FH means familial hypercholesterolemia.

Licensed Product Patents means the Shortmer Patent, and any Patent Controlled by Isis during the Term, including any Licensor Program Patents and Joint Patents, claiming nucleic acids that hybridize to a nucleic acid molecule encoding apoB, the sequence of apoB. the specific composition of matter of a Product, or methods of using Product as a therapeutic, methods of using Product to modulate apoB, and methods of using the Product to inhibit expression of apoB- and also claiming or describing (x) nucleic acids that hybridize to a nucleic acid molecule encoding a gene target other than apoB or ( y) methods of using such nucleic acids as a therapeutic or to modulate a gene target other than apoB.

Field of Use
The field of use is to treat homozygous familial hypercholesterolemia.  Homozygous familial hypercholesterolemia is a disorder where it is hard for your body to remove LDL 'bad' cholesterol from your blood. The disease raises your chances of a heart attack at an early age, but drugs and other treatments can lower your risk.

Licensee will develop and commercialize mipomersen, Isis' lipid-lowering treatment for high risk cardiovascular patients that utilizes novel antisense technology.  Mipomersen, formerly ISIS 301012, is a lipid-lowering drug targeting apolipoprotein B-100. Currently in phase 3 development, mipomersen has been shown in phase 2 trials to reduce cholesterol and other atherogenic lipids more than 40 percent beyond reductions achieved with current standard lipid-lowering drugs, enabling more patients to achieve lipid targets.

IPSCIO Record ID: 344587

License Grant
Licensor grants to the Canadian Licensee an exclusive, worldwide license under the Licensor Product-Specific Technology Patents and the Joint Patents to any Product-Specific Technology and under the Licensor Core Technology Patents, in each case solely to develop, make, have made, use, sell, offer for sale, have sold and import Products.
License Property
Licensor is a biopharmaceutical company exploiting proprietary RNA-based drug discovery technologies to identify and commercialize novel drugs.

Antisense Compound means an oligomeric compound or analog, mimic or mimetic thereof having a sequence that is partially or wholly complementary to the sequence of a messenger RNA (pre-mRNA or mRNA), viral RNA, or noncoding RNA that directly modulates RNA expression.

Product means a pharmaceutical preparation comprising any single TS ASO or Tandem selected by Licensee. After the Project Plan has been completed, the Parties will append to this Agreement the specific sequence and chemistry of each TS ASO which constitutes the active pharmaceutical ingredient in each Product.

TS ASO means a single-stranded oligonucleotide or an analog thereof that hybridizes to TS mRNA using Watson-Crick base pairing and inhibits production of TS via an RNase-H mechanism.

1. U.S. Patent No. 6,001,1653
2. PCT Publication No. WO 93/13121
3. U.S. Patent. 5,914,396
4. U.S. Patent 61451,991
5. U.S. Patent No. 6,166,197
6. U.S. Patent No. 51919,619
7. U.S. Patent No. 5,962,425
8. U.S. Patent No. 6,143,881
9. U.S. Patent No. 5,969,116
10. U.S. Patent No. 6,346,614
11. U.S. Patent No. 6,399,754
12. U.S. Patent No. 6,326,199

Field of Use
The field of use is the identification of a lead TS ASO targeted to inhibit Thymidylate Synthase.

The drug is an antisense inhibitor of thymidylate synthase (TS), a well-known drug target that protects cancer cells from the effects of several chemotherapy treatments. In preclinical studies, antisense inhibition of TS suppressed human tumor cell growth and overcame tumor cell resistance to marketed TS-targeted drugs.

TS is an important target in a wide variety of cancers including, colorectal, breast, stomach, esophageal, head and neck cancers, and mesothelioma; it is of increasing importance in non-small cell lung cancer. In addition to interfering with the effectiveness of chemotherapy, the TS gene may also participate in causing cancer. TS is a target for several chemotherapy agents, including 5-fluorouracil (5-FU), pemetrexed (Alimta®), and raltitrexed (Tomudex®).

IPSCIO Record ID: 383575

License Grant
Licensor of Switzerland grants a non-exclusive and non-transferable license, without the right to sublicense, under the Licensed Patents in the Territory with the rights to
—  incorporate Licensed Products into Licensee’s Complete Diagnostic Kits,
—  make, offer to sell and sell such Complete Diagnostic Kits in the Licensed Field, and
—  convey with the sale of such Complete Diagnostic Kits the right to use the Complete Diagnostic Kits under the Licensed Patents in the Licensed Field. Licensee’s right to use Complete Diagnostic Kits includes the right to perform evaluations and validations of Complete Diagnostic Kits, but specifically does not include the right to use Complete Diagnostic Kits for the performance of diagnostic services or testing, except that Licensee may use Complete Diagnostic Kits as End Users.
License Property
Licensor owns or controls certain Licensed Patents relating to chemically modified thermostable DNA polymerases, also known as Hot Start Enzymes, for use in polymerase chain reaction, or PCR, technology.

Licensed Product means a chemically modified thermostable DNA polymerase, the manufacture, use or sale of which is covered by one or more Valid Claims of the Licensed Patents, sold by Licensor, directly or through its distributor, or made and sold by a supplier licensed to make and sell the same.

Complete Diagnostic Kit means a Licensee manufactured and trademarked kit covered by one or more Valid Claims of the Licensed Patents, not covered by any Licensor patents other than the Licensed Patents and dedicated for use for PCR in the Licensed Field, and which Licensee manufactured and trademarked kit is comprised of, at a minimum, the essential active reagents used in the practice of PCR for nucleic acid testing in the Licensed Field. For the avoidance of doubt and for the sake of clarification, ASRs, Analyte Specific Reagents, are not Complete Diagnostic Kits.

U.S. Patent No. 5,677,152 — Issued October 14, 1997 (process and kit claims only) Nucleic Acid Amplification Using a Reversibly Inactivated Thermostable Enzyme

U.S. Patent No. 5,773,258 — Issued June 30, 1998 (process and kit claims only) Nucleic Acid Amplification Using a Reversibly Inactivated Thermostable Enzyme

U.S. Patent No. 6,127,155—Issued October 3, 2000 (reaction mixture claims only) Stabilized Thermostable Nucleic Acid Polymerase Compositions Containing Non-Ionic Polymeric Detergents

Field of Use
The Licensed Field means the field of use consisting of products or processes for the measurement, observation or determination of a disease, disease state or genetic predisposition to a disease, by detecting, quantitating, distinguishing and/or monitoring nucleic acids in samples of material originating from a human being for the medical management for that human being, but excluding
—  human identity testing, and
—  the following human disease targets Hepatitis A Virus, Hepatitis B Virus, Hepatitis C Virus, Human Immunodeficiency Virus, Human Papilloma Virus and Parvovirus B19; provided, however, that the said exclusions for the Human Papilloma Virus and Parvovirus B19 disease targets shall be limited to 3 years from the Effective Date after which time the Human Papilloma Virus and Parvovirus B19 disease targets shall be included within the Licensed Field subject to the royalty and other terms and conditions of this Agreement.

IPSCIO Record ID: 146089

License Grant
Licensor grants a nonexclusive immunity from suit under PCR Technology solely to perform Licensed Services.

Licensor grants to Licensee the right to credit the Licensor as the source of PCR Technology in Licensees promotional materials and any other materials intended for distribution.

License Property
PCR or polymerise chain reaction is a nucleic acid amplification process.

Licensed Services means the performance of an IN VITRO diagnostic procedure utilizing PCR Technology to detect the presence, absence or quantity of a nucleic acid sequence associated with a human disease or condition within the Licensed field.

The Diagnostic product shall mean an assemblage of reagents, including but not limited to reagents packaged in the form of a kit, useful in performing a Licensed Service.

The licensed credit is 'This test is performed pursuant to a license agreement with Licensor.'

Field of Use
Licensor has expertise in validating, documenting and performing sophisticated diagnostic procedures.  The field is that of human IN VITRO diagnostics solely for the detection of genetic diseases, genetic predisposition to disease, agents associated with infectious diseases, cancer; and for tissue transplant typing, including testing performed on animal tissue intended for use in xenotransplantation; Parentage determination; disease management; and clinical trials.

IPSCIO Record ID: 204343

License Grant
With this amendment, the Exclusive License shall now read,  As of the Effective Date, Licensor grants a world-wide, exclusive license under Licensed Patents, Related Patents,  Intermediates Manufacturing Know-How, Modified Base Know-How, and Licensed Know-How to make, have made, use, offer to sell, sell and import Licensed Products in the Exclusive Licensed Field (but not the right to sell Modified Bases or Intermediates that are not incorporated into oligonucleotides ).

With this amendment, for the Non-Exclusive Licenses
(a) MGB Probe Non-Exclusive License – As of the Effective Date, Licensor grants to a world-wide, non-exclusive license under Licensed Patents, Related Patents, Intermediates Manufacturing Know-How, Modified Base Know-How and Licensed Know-How to make, have made, use, offer to sell, sell and import Licensed Products in the Non-Exclusive Licensed Field (but not the right to sell Modified Bases or Intermediates that are not incorporated into oligonucleotides).

Licensor shall grant to Licensees customers a nonexclusive, world-wide, royalty-bearing license to use Licensed Products purchased from Licensee in the HIVD Field.

License Property
Pursuant to the original agreement, the Licensor has certain know-how relating to the synthesis of MGB Oligonucleotides, including MGB Oligonucleotides containing modified bases, and the design of sequence-specific probes comprising such oligonucleotides.  MGB Oligonucleotide means Licensed Product comprising an oligonucleotide having a minor-groove binding moiety covalently attached.

The licensed know-how includes chemical structures, manufacturing methods and Algorithms, object code, source code and any other embodiments of methods or processes useful for predicting the melting temperature of MGB Oligonucleotides, whether patented, copyrighted, or not.

Licensor is currently developing gene expression and single nucleotide polymorphism (SNP) assays that employ its proprietary technologies, including the Minor Groove Binder (MGB), modified bases, Eclipse(TM) Quencher, and novel fluorescent dyes. Licensor's Eclipse(TM) probe assays, scheduled for release this summer, will allow affordable, reproducible and sensitive measurement of gene expression and detection of genetic polymorphisms for academic, biotech, diagnostic and pharmaceutical researchers. The Eclipse(TM) probes will be the first proprietary product that Licensor will introduce to the commercial marketplace.

“Licensed Patents” means (1) U.S. Patent No. 5,801,155 titled Covalently Linked Oligonucleotide Minor Groove Binder Conjugates, issued September 1, 1998; (2) U.S. Patent No. 6,084,102 titled Covalently Linked Oligonucleotide Minor Groove Binder Conjugates.

Field of Use
Pursuant to the original agreement, the Exclusive Licensed Field means the 5’-Nuclease Assay Field.  The 5’-Nuclease Assay Field means the detection of a nucleic acid sequence based on the cleavage of a nucleic acid probe that is hybridized to the nucleic acid sequence by a 5’ to 3’ nuclease activity of a polymerase enzyme.

“Non-Exclusive Licensed Field” means all fields outside of the 5’-Nuclease Assay Field and outside of the Human In Vitro Diagnostics Field including, without limitation, the following (1) use of MGB Oligonuclotides as ligation probes in an oligonuclotide ligation assay, generally as described in U.S. Patent No. 4,883,750; (2) use of MGB Oligonuclotides in an assay employing a [***]; (3) use of MGB Oligonuclotides as primers in a primer extension reaction, including but not limited to a PCR reaction or a DNA sequencing reaction; and (4) use of MGB Oligonuclotides in the Real-Time Nucleic Acid Monitoring Field, to the extent that (1), (2), (3) and (4) are practiced outside of the Exclusive Licensed Field.

Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.